Investors find new formula in pharma as focus shifts from US generics

When American pharmaceutical makers got hit last week by accusations of collusion and price fixing, the tremors were felt by their peers in India. Including, among others, Aurobindo Pharma, Dr Reddy’s Laboratories, Glenmark Pharm­a­ceuticals and Taro Pharma­ceutical Industries.  Over the years, Western economies have seen brisk price erosion in drugs. Thanks to increased competition, the effects of multinationals exiting generic molecules and pastures that aren't as green as they were once. This impact on Indian pharma — specifically the listed ones, with.....
Key stories on business-standard.com are available to premium subscribers only.

Already a premium subscriber?

Subscribe to get an across device (Website, Mobile Web, Iphone, Ipad, and Android Phone applications) access to Premium content, Breaking News alerts, Industry Newsletters, Stock and Corporate news alerts, access to Archives and a lot more.